Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Summary

Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose \[RP2D\])

Timeline

Start

2018-10-29

Primary completion

2022-01-12

Completion

2022-01-12

Outcome

Outcome not reported

Stopped (Business): “Amgen decided to discontinue study because of a business decision and not because of safety reasons”

Drugs

Indications